S&T Bank’s Clovis Oncology, Inc. CLVS Stock Holding History

S&T Bank’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-60,000	Closed	-$3K	–	113
2022 Q4	$3K	Buy	60,000 +20,000	+50%	+$13.2K	﹤0.01%	111
2022 Q3	$48K	Hold	40,000	–	–	0.01%	110
2022 Q2	$72K	Buy	40,000 +20,000	+100%	+$29.5K	0.01%	124
2022 Q1	$40K	Hold	20,000	–	–	0.01%	132
2021 Q4	$54K	Hold	20,000	–	–	0.01%	138
2021 Q3	$89K	Hold	20,000	–	–	0.01%	129
2021 Q2	$116K	Hold	20,000	–	–	0.02%	129
2021 Q1	$140K	Hold	20,000	–	–	0.02%	127
2020 Q4	$96K	Buy	20,000 +10,000	+100%	+$50.6K	0.02%	127
2020 Q3	$58K	Hold	10,000	–	–	0.01%	118
2020 Q2	$68K	Sell	10,000 -10,000	-50%	-$75.7K	0.02%	114
2020 Q1	$127K	Buy	20,000 +10,000	+100%	+$80.2K	0.04%	95
2019 Q4	$104K	Hold	10,000	–	–	0.02%	93
2019 Q3	$39K	Buy	+10,000	New	+$80.9K	0.01%	82

Other funds holding CLVS

RMC

Resources Management Corp West Hartford, Connecticut $794M AUM 25.46% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return

S&T Bank's CLVS Position: Q1 2023 in Review

S&T Bank sold out of Clovis Oncology, Inc. (CLVS) in Q1 2023, closing a stake of 60,000 shares — an estimated $3K sold.

S&T Bank first reported a position in CLVS in Q3 2019 and held it in 14 quarters. The position peaked at $140K in Q1 2021. 2 funds tracked by Wall St. Rank hold CLVS as of Q1 2023.

S&T Bank reported no remaining Clovis Oncology, Inc. position as of Q1 2023 after selling out during the quarter.
S&T Bank sold 60,000 Clovis Oncology, Inc. shares in Q1 2023, an estimated $3K.
S&T Bank first reported a position in Clovis Oncology, Inc. in Q3 2019 and held it in 14 quarters.
S&T Bank's Clovis Oncology, Inc. position peaked at $140K in Q1 2021.
2 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2023.

Based on S&T Bank's 13F filing for Q1 2023, filed 9 May 2023.